Skip to main content
Wockhardt Ltd logo

Wockhardt Ltd — Investor Relations & Filings

Ticker · WOCKPHARMA ISIN · INE049B01025 LEI · 3358001OC2OX7OZAHZ33 BSE.NS Manufacturing
Open in API
Filings indexed 861 across all filing types
Latest filing 2021-09-03 Capital/Financing Update
Country IN India
Listing BSE.NS WOCKPHARMA

About Wockhardt Ltd

https://www.wockhardt.com/

Wockhardt Ltd is a research-driven global organization focused on the development and manufacturing of formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company maintains a specialized focus on drug discovery, particularly in the field of anti-infectives and New Chemical Entities (NCEs) aimed at addressing antimicrobial resistance. Its therapeutic portfolio encompasses diverse areas such as diabetes, nephrology, cardiology, and respiratory health. With a strong emphasis on research and development, the company operates multiple manufacturing facilities that comply with international regulatory standards. Wockhardt provides medical solutions across various international markets, utilizing its expertise in complex chemistry and biotechnology to address unmet clinical needs.

Recent filings

Filing Released Lang Actions
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding credit rating updates for the company's bank facilities and non-convertible debentures. It references SEBI regulation 30, which pertains to disclosure obligations for listed companies. The content is an announcement of credit rating assignments and reaffirmations, not a full financial report or detailed financial statements. The document length is short (1863 characters), and it does not contain financial statements or detailed analysis. Therefore, it is an update on financing activities, specifically credit rating information related to debt instruments. This fits best under Capital/Financing Update (CAP).
2021-09-03 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the issuance of duplicate share certificates due to lost or misplaced original certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate replacement. The content is about share certificate issuance and does not contain financial data, management discussion, voting results, or any report publication. It is a regulatory announcement related to shareholding records but does not fit into categories like Major Shareholding Notification (MRQ) or Share Issue/Capital Change (SHA) since it is about duplicate certificates, not new shares or ownership changes. This type of announcement is best classified under Regulatory Filings (RNS) as a general compliance disclosure that does not fit other specific categories.
2021-09-03 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure under Regulation 31(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, which pertains to encumbrance of shares by promoters and related parties. It includes extensive tabular data on pledge creation and release, shareholding percentages, and details of entities involved in the encumbrance. The content is regulatory in nature, focusing on share pledges and collateral related to loans, and does not contain financial statements, earnings data, or management commentary. It is not an annual report, earnings release, or any form of financial report. Instead, it is a regulatory filing disclosing substantial acquisition and encumbrance information as required by SEBI regulations. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-02 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure under Regulation 31(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, which pertains to encumbrance of shares (pledges, liens, etc.) by promoters or persons acting in concert. It includes extensive tabular data about share pledges, encumbrances, dates, amounts, and entities involved. The document is regulatory in nature, providing updates on share encumbrances and collateral related to loans. It does not contain financial statements, earnings data, management discussion, or any form of report publication. It is not a report itself but a regulatory disclosure mandated by SEBI. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-30 English
Disclosure under SEBI Takeover Regulations
Share Issue/Capital Change Classification · 95% confidence The document text primarily details the creation and release of pledges (encumbrances) on shares as collateral for loans from various financial institutions. It includes specific dates, number and percentage of shares encumbered, and names of entities involved. This type of information is typical of disclosures related to share pledges or encumbrances, which are often reported as part of shareholding or capital structure changes. There is no indication of a full financial report, earnings release, management discussion, or regulatory certification. The document is not a report publication announcement since it contains substantive data rather than just a notice. The content fits best under the category of Share Issue/Capital Change (SHA), as it relates to changes in share encumbrance status affecting capital structure.
2021-08-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership between Wockhardt and Jemincare for a novel antibiotic product. It contains no financial statements, regulatory filings, or detailed financial data. It is an announcement of a business development or collaboration, not a financial report or regulatory filing. The document is not a report itself but a communication to stock exchanges and the public about a corporate partnership. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-08-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.